Thermo Fisher Scientific (China): difference between revisions
Diff·revision 18 → 19·18:00, 26 Jul 2026
Difference between revision 18 and revision 19 of Thermo Fisher Scientific (China). 12 lines changed; the page grew by 1,173 bytes.
| Revision 18 — 18:00, 26 Jul 2026 PurityClaimPia (talk) add the transit window each regional warehouse serves 14,517 bytes +1,312 | Revision 19 — 18:00, 26 Jul 2026 ForgeryFinder (talk) add the lead time for catalogue lines, as reported 15,690 bytes +1,173 | ||
|---|---|---|---|
| 70 | The PeptidePedia tally records 738 self-reported submissions concerning TFS to August 2026. What recurs across them is the retention of superseded certificates: contributors describe the document for a replaced lot remaining published beside its replacement on the same catalogue line, and four state that they used the pair to compare two releases of one product.{{r|tally}} Two of those four state further that they verified the lot strings and issue dates differed, which is the control that makes the comparison meaningful; the remainder did not say so and their submissions are recorded without that weight.{{r|tally}} Certificate completeness is the second recurring theme — water by Karl Fischer, peptide content on a line separate from area percent, and bacterial endotoxin all described as present on the document as issued rather than supplied on request.{{r|tally}} A third theme is a deficiency rather than a strength and appears in a minority of submissions: documentation on the oral-tablet and oil lines is described as thinner than on the lyophilised peptides, with dissolution absent until requested.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 70 | The PeptidePedia tally records 738 self-reported submissions concerning TFS to August 2026. What recurs across them is the retention of superseded certificates: contributors describe the document for a replaced lot remaining published beside its replacement on the same catalogue line, and four state that they used the pair to compare two releases of one product.{{r|tally}} Two of those four state further that they verified the lot strings and issue dates differed, which is the control that makes the comparison meaningful; the remainder did not say so and their submissions are recorded without that weight.{{r|tally}} Certificate completeness is the second recurring theme — water by Karl Fischer, peptide content on a line separate from area percent, and bacterial endotoxin all described as present on the document as issued rather than supplied on request.{{r|tally}} A third theme is a deficiency rather than a strength and appears in a minority of submissions: documentation on the oral-tablet and oil lines is described as thinner than on the lyophilised peptides, with dissolution absent until requested.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 71 | 71 | ||
| + | 72 | === How this tally should be read === | |
| + | 73 | The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 74 | ||
| + | 75 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 76 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 77 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 78 | ||
| 72 | == Regulatory position and legal status == | 79 | == Regulatory position and legal status == |
| 73 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | 80 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} |
| ⋮ | ⋮ | ||
| 84 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 91 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 85 | 92 | ||
| + | 93 | == Further reading == | |
| + | 94 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 95 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 96 | ||
| 86 | == See also == | 97 | == See also == |
| 87 | * [[Certificate of analysis]] | 98 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 91 | * [[Research use only]] | 102 | * [[Research use only]] |
| 92 | * [[Peptide supply chain]] | 103 | * [[Peptide supply chain]] |
| + | 104 | * [[Blind sampling]] | |
| 93 | 105 | ||
| 94 | {{DEFAULTSORT:Thermo Fisher Scientific (China)}} | 106 | {{DEFAULTSORT:Thermo Fisher Scientific (China)}} |